SOLAR-1 clinical trial investigated the use of alpelisib, a PI3K inhibitor, along with fulvestrant for men and in postmenopausal women with HR-positive, HER2-negative advanced breast cancer [120]. Here, ERBB2 is linked to breast cancer.